Recent News

• 11.25.2025 - Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
• 11.17.2025 - Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
• 11.12.2025 - Ascendis Pharma Reports Third Quarter 2025 Financial Results
• 11.07.2025 - New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
• 11.05.2025 - Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
• 11.03.2025 - 3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
• 10.08.2025 - Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia
• 09.03.2025 - 2025 Wells Fargo Healthcare Conference

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]